Testing the drug NEO100 in people with high-grade meningioma
Original title: NEO100 and High-Grade Meningioma
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a mid stage study, so the drug is still being tested in people.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study is testing a drug called NEO100 in people whose high-grade meningioma is still there, has grown, or has come back.
Who this trial is for. This trial is for people with high-grade meningioma that is left after surgery, that scans show has grown, or that has come back. It is testing a drug called NEO100, also called perillyl alcohol, which patients take themselves four times daily on a 28-day treatment cycle.
Where it stands. The trial has not reported results. It is looking at how safe the drug is, how the body handles it, and how well it works. Those answers are not in yet.
What this means, and what it doesn't
What it could mean: This is one more option being studied for a hard to treat tumor. Someone whose situation fits this trial could ask their care team about it. The care team can help sort out whether it makes sense to look into.
What it doesn't mean: This does not mean NEO100 works. A trial is a test, not a proven treatment. Being in a trial is not a guarantee that it will help you. It is not a promise of a cure.
Source: ClinicalTrials.gov, July 16, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.